<DOC>
	<DOCNO>NCT01988493</DOCNO>
	<brief_summary>This open-label , integrate , Phase 1b/2 trial determine recommend Phase 2 dose ( RP2D ) evaluate efficacy , safety , pharmacokinetic MSC2156119J first-line treatment versus sorafenib subject MET+ , Barcelona Clinic Liver Cancer ( BCLC ) Stage C , systemic treatment naive advance hepatocellular carcinoma ( HCC ) Child-Pugh class A liver function .</brief_summary>
	<brief_title>Efficacy , Safety , Pharmacokinetic MSC2156119J Asian Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm HCC Subjects advance HCC BCLC Stage C Subjects disease progression intolerant prior standard treatment advance HCC ( phase Ib Korean subject ) A tumor biopsy require determine MET status MET+ status ( Phase 2 ) , determined central laboratory ( Phase 1b retrospectively , Phase 2 subject selection ) define protocol ChildPugh class A encephalopathy accord screen assessment Asian male female , 18 year age old Measurable disease accordance RECIST v1.1 ( Phase 2 ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 Eligible treatment sorafenib , assess investigator accord Package Insert clinical judgment ( Phase 2 ) Signed date informed consent indicate subject inform pertinent aspects trial prior enrollment Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure Life expectancy judge investigator least 3 month Prior systemic anticancer treatment advance HCC , include target therapy ( example , sorafenib ) , chemotherapy , investigational agent ( Phase 2 ) Prior treatment agent target hepatocyte growth factor ( HGF ) /cMet pathway Prior localregional therapy within 4 week prior Day 1 trial treatment Prior history liver transplant Laboratory index baseline define protocol Past current history neoplasm HCC , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix , cancer curatively treat evidence disease least 5 year Known central nervous system ( CNS ) brain metastasis either symptomatic untreated Medical history difficulty swallowing , malabsorption , chronic gastrointestinal disease , condition may hamper compliance and/or absorption test product Clinically significant gastrointestinal bleeding within 4 week trial entry Peripheral neuropathy Grade great equal 2 ( Common Terminology Criteria Adverse Events [ CTCAE ] v4.0 ) Impaired cardiac function define protocol Hypertension uncontrolled standard therapy Subject family history long QT syndrome take agent know prolong QT/QTc interval Known human immunodeficiency virus ( HIV ) infection Subjects acute pancreatitis and/or chronic pancreatitis , elevate lipase and/or amylase , clinical symptom , and/or image study indicative diagnosis ( Mainland Chinese subject ) Known suspect drug hypersensitivity ingredient sorafenib ( Phase 2 ) MSC2156119J Female subject pregnant lactating , male female reproductive potential willing able employ highly effective method birth control/contraception prevent pregnancy 2 week receive study drug 3 month receive last dose study drug Concurrent treatment nonpermitted drug Substance abuse , acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate trial participation opinion investigator Participation another clinical trial within past 28 day Previous anticancer treatmentrelated toxicity recover baseline Grade 01 ( except alopecia peripheral neuropathy ) Subjects concurrent medical condition disease potentially compromise conduction study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>MSC2156119J</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Recommended Phase 2 dose</keyword>
</DOC>